Testing a new dual-antibody treatment before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new two-in-one immunotherapy (bispecific antibody) given before surgery to shrink advanced lung cancer. It compares this approach to a standard single-antibody treatment (Toripalimab) combined with chemotherapy, to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage II or III non-small cell lung cancer and have not had any prior treatment for it.
- You are 18 years or older and are generally in good health (ECOG performance status 0 or 1).
- You do not have the EGFR mutation or ALK rearrangement in your tumor.
- You do not have an active autoimmune disease or other unstable medical conditions (like uncontrolled high blood pressure, heart disease, or active infections).
- You are willing to use effective birth control during the study and for at least 120 days after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial tests if receiving immunotherapy before surgery works better than getting it after surgery for people with stage II to IIIB non-small cell lung cancer. The goal is to see which timing helps prevent the cancer from coming back.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.